Keyword: Seattle Genetics

Scott Gottlieb goes back to biotech investing; Seattle Genetics taps first CCO; Affimed parts with CSO; and CSL Behring poaches former Biogen exec.

The former VP of clinical development at cancer biotech Seattle Genetics has jumped ship to Zymeworks.

The trial linked the antibody-drug conjugate to a 44% response rate in patients with locally advanced or metastatic urothelial cancer.

Seattle Genetics names Keytruda developer as CMO and Aravive CEO Stephen Eck leaves to join Immatics.

Seattle Genetics appointed Roger Dansey as CMO, who led Merck’s late-stage oncology work, including developing Keytruda in multiple tumor types.

Immunomedics is drawing a deeper line under its woes with a new head of research from AstraZeneca.

Both Seattle and Pieris have been busy on the deal front, and today their lists grew longer as the two pair on developing immuno-oncology treatments.

After a deal for Immunomedics fell through last May, Seattle Genetics has scaled down spending to ink a $614 million deal for Cascadian Therapeutics.

News that the Trump administration is axing the Obama-era Deferred Action for Childhood Arrivals program has been met with dismay by biotech leaders.

Seattle Genetics has called a halt to all clinical testing of vadastuximab talirine (SGN-CD33A) after seeing a higher rate of patient deaths with the drug in a phase 3 trial.